A Phase 2 Study of CIM331 for Atopic Dermatitis Patients

Inclusion Criteria:

- ≥18 and ≤65 years of age at the time of consent.

- Patients with Atopic Dermatitis

- Pruritus visual analogue scale (VAS) ≥50 mm at the screening and baseline visit

- Eczema Area and Severity Index (EASI) ≥10 at the screening and baseline visit

- static Investigator's Global Assessment (sIGA) score ≥3 at the baseline visit

Exclusion Criteria:

- Serological evidence of hepatitis B virus or hepatitis C virus infection

- Known human immunodeficiency virus infection

- Ongoing treatment with specific or non-specific hyposensitization therapy for AD

- Treatment with mild or moderately potent topical corticosteroids (TCS) within 1 week
prior to randomization

- History of infection including skin infection requiring treatment with oral or
intravenous (IV) antibiotics, antivirals, or antifungals within 1 week prior to
randomization.

- Evidence of tuberculosis (TB) infection as defined by a positive purified protein
derivative (PPD) and/or positive interferon-gamma release assay.

- Pregnant or lactating women.